Paris - Delayed Quote EUR

Median Technologies SA (ALMDT.PA)

3.6900 -0.0400 (-1.07%)

At close: 5:35:12 PM GMT+1

Median Technologies Reports H1 2026 Financial Results and Q3 Business Highlights

Business Wire 6d ago

ALMDT.PA
-1.07%
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ESMO 2026

Business Wire 14d ago

ALMDT.PA
-1.07%
Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York

Business Wire 15d ago

ALMDT.PA
-1.07%
eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026

Business Wire 21d ago

ALMDT.PA
-1.07%
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30, 2026

Business Wire 23d ago

ALMDT.PA
-1.07%
Median Technologies: H2 2026 Financial Communication Calendar

Business Wire 1mo ago

ALMDT.PA
-1.07%
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31, 2026

Business Wire 1mo ago

ALMDT.PA
-1.07%
Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy

Business Wire 2mo ago

ALMDT.PA
-1.07%
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026

Business Wire 2mo ago

ALMDT.PA
-1.07%
Canon Medical Systems’ Olea Medical to Expand U.S. Access to eyonis® LCS for AI-Powered Lung Cancer Screening

GlobeNewswire 3mo ago

ALMDT.PA
-1.07%
Median Technologies and Olea sign partnership for lung cancer device

Medical Device Network 3mo ago

ALMDT.PA
-1.07%
Median Technologies and Olea sign partnership for lung cancer device

Hospital Management 3mo ago

ALMDT.PA
-1.07%

U.S. markets closed

Median Technologies SA (ALMDT.PA)

Median Technologies Reports H1 2026 Financial Results and Q3 Business Highlights

Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ESMO 2026

Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York

eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30, 2026

Median Technologies: H2 2026 Financial Communication Calendar

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of August 31, 2026

Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026

Canon Medical Systems’ Olea Medical to Expand U.S. Access to eyonis® LCS for AI-Powered Lung Cancer Screening

Median Technologies and Olea sign partnership for lung cancer device

Median Technologies and Olea sign partnership for lung cancer device